Drugs / JNJ-64041575
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03189498 | Jul → Dec 2017 | impaired renal function disease | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT03105986 | Apr → Jun 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03010059 | Feb → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64041575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03010059 ↗ |
| Route | Oral | “following administration of a single oral dose of JNJ-64041575” NCT03010059 ↗ |